Status:
COMPLETED
Quercetin In The Treatment Of SARS-COV 2
Lead Sponsor:
Hôpital Universitaire Sahloul
Conditions:
SARS (Severe Acute Respiratory Syndrome)
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name "vitam...
Detailed Description
Properties * Anti-oxidant, vascular protector * Inhibition of platelet aggregation, vasorelaxant , arterial relaxant * Anti-hypertensive , especially by certain derivatives (quercetin-3-glucuronic ac...
Eligibility Criteria
Inclusion
- • Clinical score greater than 6
- Patients with clinical symptoms less than 5 days old.
- Men and women at least 40 years old, able and willing to give informed consent;
- Any patient over the age of 18 with a CT scan in favor of COVID-19;
- Ambulatory or hospitalized environment;
- Patient with dyspnea or with a positive gait test;
- The patient must have at least one of the following high risk criteria: 70 years or older, obesity (BMI ≥ 30 kg / m2), diabetes mellitus, uncontrolled hypertension (systolic blood pressure ≥ 150 mm Hg), respiratory disease known (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary artery disease, fever ≥ 38.4 ° C within the last 48 hours, dyspnea at the time of presentation, bicytopenia, pancytopenia or a combination of a number high neutrophils and low lymphocytes count;
- The patient is not of childbearing age, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing age and uses at least one method of contraception and preferably two complementary forms of contraception comprising a method of barrier throughout the study and for 30 days after the end of the study;
- The patient must be able and willing to comply with the requirements of this study protocol.
Exclusion
- • Patient currently in shock or exhibiting hemodynamic instability;
- Patient with inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption;
- Pregnant or breastfeeding patient
- Patient with a history of allergic reaction or significant sensitivity to Nigella;
- The patient is considered by the investigator, for whatever reason, to be an unsuitable candidate for the study.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04853199
Start Date
June 1 2021
End Date
August 30 2021
Last Update
July 6 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
HU Sahloul, sousse, Tunisia
Sousse, Itinéraire Ceinture Cité Sahloul, Tunisia, 4054
2
Riadh Boukef
Sahloul, Sousse Governorate, Tunisia